Annual report pursuant to Section 13 and 15(d)

RFS Pharma, LLC Acquisition (Tables)

RFS Pharma, LLC Acquisition (Tables)
12 Months Ended
Dec. 31, 2016
Business Combinations [Abstract]  
Schedule of Purchase Price Consideration

Based upon the estimated fair values determined by the Company, the total purchase price was allocated as follows (in thousands):


Purchased in-process research and development   $ 184,966  
Net book value of tangible assets acquired     (183 )
Goodwill     65,195  
Deferred tax liability     (65,195 )
Total purchase price   $ 184,783